|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
|
Medtronic received information regarding a pipeline flex that failed to open at the distal end and then experienced friction and deployed prematurely.The patient was undergoing a procedure for flow diversion treatment of a right internal carotid artery (r-ica) cavernous segment unruptured amorphous giant thrombosed aneurysm.The aneurysm max diameter was 33mm and the neck diameter was 30mm.The distal landing zone was 3.7mm; the proximal landing zone was 4.8mm.Vessel tortuosity was severe.Dual antiplatelet treatment (dapt) was administered with normal pru level noted.It was reported that after access was established and the phenom 27 microcatheter was positioned, the surgeon measure the entire length of the vessel to be covered, which was 60mm, with the distal vessel being extremely tortuous.It was planned for a non-medtronic stent and pipeline flex bridging treatment.The long non-mdt stent was initially selected, which was successfully delivered and deployed. after that, considering the tortuous vessel, there were concerns that an overly long stent might affect proper delivery and positioning, and the proximal vessel near the aneurysm neck was not suitable for excessive coverage.Therefore, ped-500-25 was selected.The pipeline was delivered but during deployment, the stent distal tip could not be opened when less than 50% of the stent was deployed.The pipeline was not positioned in a bend.The pipeline was resheathed and redeployed more than two times and the surgeon was able to successfully open and position the pipeline stent stip.However, the pipeline had deployed from the pushwire and could no longer be controlled with the pushwire.After several failed attempted, the intermediate catheter was advanced, and the plan was to directly retract the microcatheter to pull the stent into the intermediate catheter.However, during this retraction process, the s tent was forcibly detached due to friction, but its landing position ended up at the proximal end of the entire aneurysm neck, failing to bridge with the already implanted stent for coverage of the aneurysm.However, it was noted that full wall apposition was achieved.Another pipeline (ped-500-20) was then used, which was successfully deployed to complete the procedure.There were no patient symptoms or complication associated with this event.Ancillary devices: phenom 27 microcatheter, navein 5f 125cm distal access catheter, tb plus 5.5-45 stent.Additional information was received reporting that the cause of the failure to open was that the stent's distal end appeared rod-like or fish-mouth-shaped and required multiple attempts to open.The exact cause is unclear and isbeing discussed with the customer.The friction occurred where the stent came into contact and scraped against the navien catheter and the vascular wall.The tip of the catheter moved during pipeline deployment.There was no rotation of the pushwire, but there was some pulling back.
|
|
Additional information was received reporting that the report that "the tip of the catheter moved during pipeline deployment" is not referring to catheter kickback.There was resistance during delivery or positioning.The pipeline jumped during deployment.After unloading the ped-500-25, a new one was used for deployment to complete the procedure.There was movement of the catheter tip during the first half of the deployment, but no movement in the second half.This involved both the navien and phenom.
|
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|